Cargando…

PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer

BACKGROUND: The programed death ligand-1 combined positive score (PD-L1 CPS), the only FDA-approved biomarker for immune checkpoint inhibitor therapy in gastric cancer (GC) patients, is an important but imperfect predictive biomarker. The molecular characteristics of tumors that influence the PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Langbiao, Niu, Lei, Zheng, Xue, Xiao, Fei, Sun, Huaibo, Deng, Wei, Cai, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586003/ https://www.ncbi.nlm.nih.gov/pubmed/37868079 http://dx.doi.org/10.1177/17588359231205853

Ejemplares similares

A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations
por: Niu, Lei, et al.
Publicado: (2023)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

PD-L1 Induces Epithelial–Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway
por: Fei, Zhenghua, et al.
Publicado: (2019)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
por: Wang, Zhenghang, et al.
Publicado: (2022)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

Upregulation of MTHFD2 is associated with PD-L1 activation in bladder cancer via the PI3K/AKT pathway
por: Deng, Xinxi, et al.
Publicado: (2022)

PD-L1 degradation pathway and immunotherapy for cancer
por: Gou, Qian, et al.
Publicado: (2020)

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
por: Gao, Yang, et al.
Publicado: (2020)

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression
por: Zhu, Xiaodan, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Determination of the branching ratios $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi^{+}\pi^{-}\pi^{0})$ and $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi e\nu)$
por: Kreutz, A., et al.
Publicado: (1994)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
por: Isoyama, Sho, et al.
Publicado: (2021)

PD-L1(P146R) is prognostic and a negative predictor of response to immunotherapy in gastric cancer
por: Li, Qing, et al.
Publicado: (2022)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Protoniumvernichtung in $K_{L}^{0} K^{\pm} \pi^{\mp} \pi^{0}$ und $K_{L}^{0} K^{\pm} \pi^{\mp} \pi^{0} \pi^{0}$
por: Kolo, C
Publicado: (1995)

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy
por: Li, Anlin, et al.
Publicado: (2023)

UBAP2L promotes gastric cancer metastasis by activating NF-κB through PI3K/AKT pathway
por: Li, Ou, et al.
Publicado: (2022)

$ K _{L} -K _{S} $ regeneration phase and the relative phase of the amplitudes for the decay of $ K _{L} $ and $ K _{S} $ into $\pi ^{+}$ and $\pi ^{-}$
por: Rubbia, Carlo, et al.
Publicado: (1966)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
por: Hu, Xiaoqian, et al.
Publicado: (2023)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

4579 Distinct clinical and immunological responses to αPD-1, kαPD-L1 and αPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
por: Garcia, Myrna G, et al.
Publicado: (2020)

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas
por: Han, Song, et al.
Publicado: (2021)

$K_{S}$ and $K_{L}$ interference in the $\pi^{+} \pi^{-}$ decay mode, CP invariance and the $K_{S}-K_{L}$ mass difference
por: Alff-Steinberger, C, et al.
Publicado: (1966)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

A measure of the ratio of the rates $\frac{K_{L}\rightarrow 3 \pi^{0}}{K_{L}\rightarrow \pi^{+}\pi^{-}\pi^{0}}$ and $\frac{K_{L}\rightarrow 3 \pi^{0}}{K_{L}\rightarrow all charged}$
Publicado: (1967)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

A measurement of the ratios of the rates $K^{0}_{L}$ -> 3 $\pi^{0}$ / $K^{0}_{L}$ -> $\pi^{+} \pi^{-} \pi^{0}$ , $K^{0}_{L}$ -> 3 $\pi^{0}$ / $K^{0}_{L}$ -> all charged modes and $K^{0}_{L}$ -> $\pi \mu \nu$ / $K^{0}_{L}$ -> $\pi$ e $\mu$ , and test of the $\delta$ I = 1/2 rule
por: Budagov, I A, et al.
Publicado: (1968)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues
por: Zhuang, Hongqing
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7md978md38deak7c6immvj6bu5